Spicer Steps Down As CFO Of NovaDel
Deni M. Zodda, NovaDel Pharma's chief business officer, has been appointed interim CFO and corporate secretary. Zodda joined the company in 2007, and has been responsible for our business development activities.
He was previously the interim CFO at StemCapture, SVP of business development and principal financial officer at Discovery Laboratories and managing director and head of biotechnology at the corporate finance group at KPMG.
NovaDel Pharma has hired Joseph M. Warusz as a consultant, to serve as principal accounting officer of the company. Since March of 2006, Warusz has been providing consulting services to a range of clients in the life sciences sector. From August 2005 to March 2006, he was VP of finance of Amicus Therapeutics.
Flemington, New Jersey-based NovaDel Pharma is a specialty pharmaceutical company developing oral spray formulations for a range of marketed drugs. The company's most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system.
FinancialWire" ( http://www.financialwire.net ), an independent, proprietary news service of Investrend Communications, Inc., receives no compensation for its news or opinions. Further disclosure is at http://www.investrend.com/articles/secondlevel.asp?level=472 . To contact FinancialWire" write to inquiries@financialwire.net .
Free annual reports for companies mentioned in the news are accessible via http://investrend.ar.wilink.com/?level=279 .
Copyright(C)2009 by financialwire.net, Inc. All rights reserved.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
